Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 601–700 of 3,636
Du, H., Li, X., Su, N., Li, L., Hao, X., Gao, H., Kwong, J. S.-W., Vandvik, P. O., Yang, X., Németh, I., et al. (2019) · Heart · doi:10.1136/heartjnl-2019-314763 · Cited by 42
Suzuki, K., Oikawa, T., Nochioka, K., Miura, M., Kasahara, S., Sato, M., Aoyanagi, H., Shiroto, T., Takahashi, J. A., Miyata, S., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312336 · Cited by 39
Alkhalil, M., Kearney, A., Hegarty, M., Stewart, C., Devlin, P., Owens, C. G., & Spence, M. S. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.05.021 · Cited by 40
The emerging landscape of peptide-based inhibitors of PCSK9
Tombling, B. J., Zhang, Y., Huang, Y., Craik, D. J., & Wang, C. K. L. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.903 · Cited by 37
Jegier, A., Szalewska, D., Mawlichanów, A., Bednarczyk, T., Eysymontt, Z., Gałaszek, M., Mamcarz, A., Mierzyńska, A., Piotrowicz, E., Piotrowicz, R., et al. (2021) · Kardiologia Polska · doi:10.33963/kp.a2021.0066 · Cited by 49
Korneva, V., Kuznetsova, T. Y., & Julius, U. (2021) · Biomedicines · doi:10.3390/biomedicines9091271 · Cited by 39
PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs
Kuzmich, N. N., Andresyuk, E., Porozov, Y. B., Tarasov, V. V., MIu, S., Preferanskaya, N., Veselov, V. V., & Alyautdin, R. N. (2022) · Molecules · doi:10.3390/molecules27020434 · Cited by 35
Circulating Cytokines in Myocardial Infarction Are Associated With Coronary Blood Flow
Kalinskaya, A. I., Dukhin, O., Lebedeva, А., Maryukhnich, E., Rusakovich, G., Vorobyeva, D., Shpektor, A., Margolis, L. B., & Vasilieva, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837642 · Cited by 37
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
(2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.05.011 · Cited by 36
Köenig, W., Conde, L. G., Landmesser, U., Leiter, L. A., Ray, K. K., Schwartz, G. G., Wright, R. S., Han, J., & Raal, F. J. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07413-0 · Cited by 37
“New therapies targeting proprotein convertase subtilisin/ kexin type 9 (PCSK9) have been previously shown effective in lowering LDL-C levels and CV events [22, 23].”
BackgroundSelf-citationLipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Rossi, M., Fabris, E., Barbisan, D., Massa, L., & Sinagra, G. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00497-3 · Cited by 36
PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction
Mátyás, C., Trojnár, E., Zhao, S., Arif, M., Mukhopadhyay, P., Kovács, A. D., Fábián, A., Tokodi, M., Bagyura, Z., Merkely, B. P., et al. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.06.005 · Cited by 37
Qin, T., Ma, T., Huang, K., Lu, S., Zhong, J., & Li, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01215-5 · Cited by 44
“Three PCSK9 inhibitor drugs are currently on the market: Evolocumab [85], Alirocumab [86], and Inclisiran [87].”
BackgroundCardiovascular Risk Estimation and Stratification Among Individuals with Hypercholesterolemia
Bosco, G., Mszar, R., Piro, S., Sabouret, P. F., & Gallo, A. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01225-3 · Cited by 42
“…Coronary Syndrome During Treatment With Alirocumab (ODYSSEY) Outcomes trials also showed that proprotein-convertase subtilisin kexin-9 (PCSK9) inhibitors provided further decrease in LDLc plasma levels in patients with ASCVD, resulting in a 15% reduction of incident cardiovascular events [14, 15].”
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia
Vafai, S. B., Täubel, J., Ashdown, T., Patel, R. S., Diamondali, S., Cegla, J., Soran, H., Bashir, B., Abitbol, A., Gaudet, D., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2601283 · Cited by 67
Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)
Waldmann, E., & Parhofer, K. G. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.016 · Cited by 35
Cardiometabolic Medicine: Development of a New Subspecialty
Saxon, D. R., Reiter–Brennan, C., Blaha, M. J., & Eckel, R. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa261 · Cited by 38
New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention
Katsanos, A. H., & Hart, R. G. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2494 · Cited by 37
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
Kosmas, C. E., Skavdis, A., Sourlas, A., Papakonstantinou, E. J., Genao, E. P., Uceta, R. E., & Guzman, E. (2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s288831 · Cited by 58
Scicali, R., Pino, A. D., Ferrara, V., Rabuazzo, A. M., Purrello, F., & Piro, S. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01703-z · Cited by 35
Lepor, N. E., Sun, J., Cantón, G., Contreras, L., Hippe, D. S., Isquith, D. A., Balu, N., Kedan, I., Simonini, A. A., Yuan, C., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.008 · Cited by 37
PCSK9-targeted therapies: present and future approaches
Rifai, M. A., & Ballantyne, C. M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00634-0 · Cited by 37
Ji, C., Bai, J., Zhou, J., Zou, Y., & Yu, M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15460 · Cited by 37
“According to recent clinical trials, such as FOURIER and ODYSSEY, both alirocumab and evolocumab can effectively lower LDL-C levels when administered with background statin therapy, reducing the risk of cardiovascular events.(15,16) Alirocumab and evolocumab reportedly exhibit good safety and tolerability, along with…”
ResultUeng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 48
Colhoun, H. M., Leiter, L. A., Müller-Wieland, D., Cariou, B., Ray, K. K., Tinahones, F. J., Domenger, C., Letierce, A., Israel, M., Samuel, R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0991-1 · Cited by 33
Ziogos, E., Chelko, S. P., Harb, T., Engel, M., Vavuranakis, M., Landim-Vieira, M., Walsh, E. M., Williams, M. S., Lai, S., Halushka, M. K., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad051 · Cited by 36
MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment
Burnett, J. R., & Hooper, A. J. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2267972 · Cited by 38
“…namely alirocumab (Sanofi/Regeneron) and evolocumab (Amgen) [9,10], have been in clinical use since 2015 and in randomized controlled trials have been shown to potently lower LDL-cholesterol and reduce cardiovascular events in patients with ASCVD when given subcutaneously fortnightly [11,12].”
MethodMu, G., Xiang, Q., Zhou, S., Liu, Z., Qi, L., Jiang, J., Gong, Y., Xie, Q., Wang, Z., Zhang, H., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01259-4 · Cited by 39
“The recent published alirocumab randomized controlled trial (RCT) in patients at high risk of CV disease named ODYSSEY OUTCOMES [18] provides clear evidence of its clinical benefit.”
BackgroundDalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
Schwartz, G. G., Leiter, L. A., Ballantyne, C. M., Barter, P. J., Black, D. M., Kallend, D. G., Laghrissi‐Thode, F., Leitersdorf, E., McMurray, J. J. V., Nicholls, S. J., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2204 · Cited by 39
Self-citationKim, H. K., Ahn, Y., Chang, K., Jeong, Y., Hahn, J., Choo, E. H., Kim, M. C., Kim, H.-S., Kim, W., Cho, M., et al. (2020) · Korean Circulation Journal · doi:10.4070/kcj.2020.0196 · Cited by 32
Familial hypercholesterolaemia: history, diagnosis, screening, management and challenges
Schmidt, E. B., Hedegaard, B. S., & Retterstøl, K. (2020) · Heart · doi:10.1136/heartjnl-2019-316276 · Cited by 35
Song, L., Zhao, X., Chen, R., Li, J., Zhou, J., Liu, C., Zhou, P., Wang, Y., Chen, Y., Zhao, H., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01519-3 · Cited by 36
Laufs, U., Catapano, A. L., Caterina, R. D., Schiele, F., Sionís, A., Zaman, A., & Jukema, J. W. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107141 · Cited by 38
Self-citationTafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4)
Qi, L., Liu, D., Qu, Y., Chen, B., Meng, H., Zhu, L., Li, L., Wang, S., Liu, C., Zheng, G., et al. (2023) · JACC Asia · doi:10.1016/j.jacasi.2023.04.011 · Cited by 40
Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22013 · Cited by 40
A critical review of chronic kidney disease as a risk factor for coronary artery disease
Coyle, M., Flaherty, G. T., & Jennings, C. S. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100822 · Cited by 45
Gene editing for dyslipidemias: New tools to “cut” lipids
Stankov, S. G., & Cuchel, M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.010 · Cited by 36
Bagheri, B., Feyzabadi, Z. K., Nouri, A., Azadfallah, A., Ari, M. M., Hemati, M., Darban, M., Toosi, P. A., & Banihashemian, S. Z. (2024) · Mediators of Inflammation · doi:10.1155/2024/5830491 · Cited by 41
“The greatest absolute reduction was observed in the subgroup of patients with the highest baseline LDL-C levels (100 mg/dL) [126].”
BackgroundLupo, M. G., Macchi, C., Marchianò, S., Cristofani, R., Greco, M. F., Dall’Acqua, S., Chen, H., Sirtori, C. R., Corsini, A., Ruscica, M., et al. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.06.001 · Cited by 32
Mahmood, T. A., Minnier, J., Ito, M. K., Li, Q. H., Koren, A., Kam, I. W., Fazio, S., & Shapiro, M. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320915803 · Cited by 33
Gene-based therapy in lipid management: the winding road from promise to practice
Tromp, T. R., Stroes, E. S. G., & Hovingh, G. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757070 · Cited by 34
Choi, Y., Lee, S. J., Kim, H. I., Lee, H. J., Kang, S. J., Kim, T. Y., Cheon, C., & Ko, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-76224-w · Cited by 40
Kim, Y., Levin, G., Nikolov, N. P., Abugov, R., & Rothwell, R. (2020) · Arthritis Care & Research · doi:10.1002/acr.24549 · Cited by 32
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.964 · Cited by 39
“The Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome with Alirocumab (ODYSSEY Outcomes) trial randomized patients to placebo or to alirocumab at 1 to 12 months after hospitalization for acute coronary syndrome [83].”
MethodDyrbuś, K., Gąsior, M., Desperak, P., Trzeciak, P., Nowak, J. U., Penson, P. E., Osadnik, T., & Banach, M. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.08.024 · Cited by 33
A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent
Hardy, J., Niman, S., Goldfaden, R. F., Ashchi, M., Bisharat, M. B., Huston, J., Hartmann, H., & Choksi, R. R. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00499-1 · Cited by 36
Lin, S.-Y., Baumann, K. J., Zhou, C., Zhou, W., Cuellar, A. E., & Xue, H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.35371 · Cited by 33
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
Jia, X., Rifai, M. A., Saeed, A., Ballantyne, C. M., & Virani, S. S. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s275739 · Cited by 35
“However, elevated hs-CRP identified higher risk individuals who derive greater absolute risk reduction from the use of PCSK9 inhibitors.(8,32,33)”
BackgroundResultFerri, N., Ruscica, M., Lupo, M. G., Vicenzi, M., Sirtori, C. R., & Corsini, A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106439 · Cited by 35
Emerging agents for the treatment and prevention of stroke: progress in clinical trials
Safouris, A., Magoufis, G., & Tsivgoulis, G. K. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1985463 · Cited by 32
Margiana, R., Alsaikhan, F., Al‐Awsi, G. R. L., Patra, I., Sivaraman, R., Fadhil, A. A., Al-Baghdady, H. F. A., Qasim, M. T., Hameed, N. M., Mustafa, Y. F., et al. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110471 · Cited by 63
European guidelines for the treatment of dyslipidaemias: New concepts and future challenges
Pirillo, A., Casula, M., & Catapano, A. L. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106936 · Cited by 42
Carramolino, L., Albarrán-Juárez, J., Markov, A., Hernández‐SanMiguel, E., Sharysh, D., Cumbicus, V., Morales‐Cano, D., Labrador-Cantarero, V., Møller, P. L., Nogales, P., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00412-w · Cited by 33
“Even at the lowest ApoB lipoprotein concentrations achieved with drug therapy, the average shrinkage of lesions is small and there is a considerable residual risk of new clinical events 37,38 .”
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature
Schonck, W. A. M., Stroes, E. S. G., Hovingh, G. K., & Reeskamp, L. F. (2024) · Drugs · doi:10.1007/s40265-024-01995-9 · Cited by 38
“The efficacy of PCSK9 mAbs, exemplified by the FOURIER and ODYSSEY OUT-COMES trials investigating evolocumab and alirocumab in high-risk patients receiving maximally tolerated statins and/or ezetimibe, has been studied extensively [13, 57].”
BackgroundMethodA promising therapy for fatty liver disease: PCSK9 inhibitors
Han, L., Wu, L., Yin, Q., Li, L., Zheng, X., Du, S., Huang, X., Bai, L., Wang, Y., & Bian, Y. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155505 · Cited by 31
Alradwan, I. A., Fayez, N. A., Alomary, M. N., Alshehri, A. A., Aodah, A. H., Almughem, F. A., Alsulami, K. A., Aldossary, A. M., Alawad, A. O., Tawfik, Y. M. K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081037 · Cited by 50
“Studies, such as Schwartz et al.’s 2020 landmark trial, underscore their efficacy in reducing LDL-C and cardiovascular risk, marking a significant advancement in treating hypercholesterolemia and preventing cardiac events [28].”
MethodBradley, C. K., Shrader, P., Sanchez, R. J., Peterson, E. D., & Navar, A. M. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.06.008 · Cited by 31
Wiviott, S. D., Giugliano, R. P., Morrow, D. A., Ferrari, G. M. D., Lewis, B. S., Huber, K., Kuder, J., Murphy, S. A., Forni, D. M., Kurtz, C. E., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0764 · Cited by 33
Cao, Y., Zhang, H., Jin, J., Liu, H., Zhang, Y., Xu, R., Gao, Y., Guo, Y., Zhu, C., Hua, Q., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000746 · Cited by 32
Blanchard, V., Chemello, K., Hollstein, T., Chong-Hong-Fong, C., Schumann, F., Grenkowitz, T., Nativel, B., Coassin, S., Croyal, M., Kassner, U., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab247 · Cited by 36
Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies
Handhle, A., Viljoen, A., & Wierzbicki, A. S. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s266244 · Cited by 32
Cerebrovascular Disease and Statins
Beltrán, L. M., Vallejo‐Vaz, A. J., & Grijalvo, O. M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.778740 · Cited by 33
“Results from randomized controlled trials of PCSK9 inhibitors added on top of statins, including FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) with evolocumab (25, 26), ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome Dur…”
ResultCordero, A., Olmo, M. R. F., Quiroga, G. A. C., Romero‐Menor, C., Fácila, L., Seijas‐Amigo, J., Fornovi, A., Murillo, J. R., Rodríguez‐Mañero, M., Mora, M. C. B., et al. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001205 · Cited by 36
Volpe, M., Gallo, G., Modena, M. G., Ferri, C., Desideri, G., Tocci, G., Members of the Board of the Italian Society of Cardiovascular Prevention, Bellone, S., Bertolotti, M., Biffi, A., et al. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00503-4 · Cited by 35
Gao, Y., Pan, Y., Han, S., Chen, W., Jing, J., Wang, C., Yang, Y., Wang, T., Meng, X., Zhao, X., et al. (2023) · Stroke and Vascular Neurology · doi:10.1136/svn-2022-002084 · Cited by 34
Evolving Diagnostic and Management Advances in Coronary Heart Disease
Ribeiro, M. D. O. L., Correia, V. M., de Oliveira, L. L. H., Soares, P. R., & Scudeler, T. L. (2023) · Life · doi:10.3390/life13040951 · Cited by 44
“PRS has been analyzed in the populations of the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) [79] and Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab (ODYSSEY OUTCOMES) [80] trials of proprotein convertas…”
MethodPCSK9 inhibitors for acute coronary syndrome: the era of early implementation
Chen, H., & Chen, X. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1138787 · Cited by 38
“In addition, some studies have also suggested that early PCSK9 inhibitors may lead to several mild adverse effects such as injection-site reactions (17, 18, 64).”
BackgroundNew Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
Oostveen, R. F., Khera, A. V., Kathiresan, S., Stroes, E. S. G., Fitzgerald, K., Harms, M. J., Oakes, B. L., & Kastelein, J. J. P. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317963 · Cited by 31
Efficacy and Safety of Inclisiran in Asian Patients
Huo, Y., Lesogor, A., Lee, C. W., Chiang, C.-E., Mena-Madrazo, J., Poh, K. K., Jeong, M. H., Maheux, P., Zhang, M., Wei, S., et al. (2024) · JACC: Asia · doi:10.1016/j.jacasi.2023.09.006 · Cited by 31
PCSK9 Inhibitors in Secondary Prevention—An Opportunity for Personalized Therapy
Chase Board, Kelly, M. S., Shapiro, M. D., & Dixon, D. L. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000809 · Cited by 30
Lipid-Modifying Therapies and Stroke Prevention
Hackam, D. G., & Hegele, R. A. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01197-4 · Cited by 37
Sex Differences in Cardiovascular Outcomes and Cholesterol-Lowering Efficacy of PCSK9 Inhibitors
Rivera, F. B., Cha, S. W., Aparece, J. P., Rocimo, A. M. R., Ong, B., Golbin, J. M., Alfonso, P. G., Enkhmaa, B., Khan, S. U., Cainzos‐Achirica, M., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100669 · Cited by 37
Improving Stroke Risk Factor Management Focusing on Health Disparities and Knowledge Gaps
Sur, N. B., Kozberg, M. G., Desvigne-Nickens, P. M., Silversides, C. K., Bushnell, C., Goldstein, L. B., Saver, J. L., Broderick, J. P., Gökçal, E., Merino, J. G., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.040449 · Cited by 40
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
Tsioulos, G., Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Kotsi, E., Christodoulatos, G. S., Tsilingiris, D., Karampela, Ι., Skourtis, A., & Dalamaga, Μ. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063537 · Cited by 38
“In the FOURIER and ODYSSEY OUTCOMES trials, which included over 100,000 patient-years of placebo-controlled observation, treatment with PCSK9 monoclonal antibodies resulted in a median reduction of Lp(a) levels by 27% and 23%, respectively [198,199].”
MethodLiu, Y., Wang, W., Cui, X., Lyu, J., & Xie, Y. (2024) · Stroke · doi:10.1161/strokeaha.123.044424 · Cited by 32
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 35
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field
Barbagallo, F. D. G., Andreychuk, N., Scicali, R., González-Lleó, A. M., Piro, S., Masana, L., & Ibarretxe, D. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01271-x · Cited by 38
“This may be due to the early termination of both studies because of clear benefits observed in interim analyses, limiting the observation period to slightly more than two years [17, 18].”
Feingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 50
PCSK9 inhibitors in clinical practice: Novel directions and new experiences
Rallidis, L. S., Skoumas, I., Liberopoulos, E. N., Vlachopoulos, C. V., Kiouri, E., Koutagiar, I. P., Anastasiou, G., Kosmas, N., Elisaf, M., Tousoulis, D., et al. (2019) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2019.10.003 · Cited by 34
Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes
Ramin‐Mangata, S., Wargny, M., Pichelin, M., May, C. L., Thedrez, A., Blanchard, V., Nativel, B., Santos, R. D., Benseñor, I. M., Lotufo, P. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.11.027 · Cited by 35
Puri, R., Mehta, V., Duell, P. B., Nair, D. R., Mohan, J. C., Yusuf, J., Dalal, J. J., Mishra, S., Kasliwal, R. R., Agarwal, R., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.006 · Cited by 30
Masson, W. M., Lobo, M., Siniawski, D. A., Molinero, G., Masson, G., Huerin, M. S., & Nogueira, J. P. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01297-5 · Cited by 31
“clinical evident atherosclerotic disease [13, 29].”
BackgroundCordero, A., Rodríguez‐Mañero, M., Fácila, L., Fernández-Olmo, M. R., Gómez-Martínez, M. J., Valle, A., Castellano, J. M., Toro, M. M., Seijas‐Amigo, J., Vicedo-López, Á., et al. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00557-6 · Cited by 33
Ying, H., Wang, J., Shen, Z., Wang, M., & Zhou, B. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07045-2 · Cited by 35
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
Cybulska, B., Kłosiewicz−Latoszek, L., Penson, P. E., Nabavi, S. M., Lavie, C. J., & Banach, M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.12.008 · Cited by 33
Dyslipidemia in Patients with Kidney Disease
Thobani, A., & Jacobson, T. A. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.008 · Cited by 36
Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention
Furtado, R. H. M., Fagundes, A. A., Oyama, K., Zelniker, T. A., Tang, M., Kuder, J. F., Murphy, S. A., Hamer, A., Wang, H., Keech, A. C., et al. (2022) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.121.011382 · Cited by 37
Povsic, T. J., Korjian, S., Bahit, M. C., Chi, G., Duffy, D., Alexander, J. H., Vinereanu, D., Tricoci, P., Mears, S. J., Deckelbaum, L. I., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.396 · Cited by 32
Self-citationBallard‐Hernandez, J., & Sall, J. (2023) · Nursing Clinics of North America · doi:10.1016/j.cnur.2023.05.002 · Cited by 53
VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
Vroom, M. M., Lu, H., Lewis, M., Thibodeaux, B. A., Brooks, J. K., Longo, M. S., Ramos, M. M., Sahni, J., Wiggins, J., Boyd, J. D., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100497 · Cited by 31
“In addition, clinical trials with PCSK9 inhibitors revealed neither treatment-related increase in the risk of new-onset diabetes nor the exacerbation of pre-existing glycemia, both of which are known, undesirable, side effects of statin medications (10 – 14).”
BackgroundRecaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia
Sun, Y., Lv, Q., Guo, Y., Wang, Z., Huang, R., Gao, X., Han, Y., Yao, Z., Zheng, M., Luo, S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.09.012 · Cited by 32
Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S)
Strandberg, T. E., Kovanen, P. T., Lloyd‐Jones, D. M., Raal, F. J., Santos, R. D., & Watts, G. F. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02089-0 · Cited by 30
Shin, J., Chung, J., Jang, H.-S., Lee, J., Hong, K., Bang, O. Y., Kim, G., & Seo, W. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319830503 · Cited by 33
Cannon, C. P., de Lemos, J. A., Rosenson, R. S., Ballantyne, C. M., Liu, Y., Yazdi, D., Elliott‐Davey, M., Mues, K. E., Bhatt, D. L., & Kosiborod, M. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.10.014 · Cited by 32
Self-citationTardif, J., Dubé, M., Pfeffer, M. A., Waters, D. D., Köenig, W., Maggioni, A. P., McMurray, J. J. V., Mooser, V., White, H. D., Heinonen, T. M., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.01.007 · Cited by 30
Self-citationConcepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease
Mathew, R. O., Rosenson, R. S., Lyubarova, R., Chaudhry, R., Costa, S. P., Bangalore, S., & Sidhu, M. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07020-x · Cited by 32
“More recently, the ODYSSEY OUTCOMES trial examined the efficacy of alirocumab in secondary prevention of major adverse cardiovascular events in those with recent ACS (1–12 m prior to enrollment) and LDL-C levels > 70 mg/dL, nonHDL-C > 100 mg/dL, or an Apo B > 80 mg/dL; subgroup analysis in CKD has not yet been reporte…”
MethodProprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism
Guo, S., Xia, X.-D., Gu, H.-M., & Zhang, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6082-8_9 · Cited by 36
Estimation of the major cardiovascular events prevention with Inclisiran
Cordero, A., Santos‐Gallego, C. G., Fácila, L., Rodríguez‐Mañero, M., Bertomeu‐González, V., Castellano, J. M., Seijas‐Amigo, J., Núñez, J. E., Zuazola, P., González‐Juanatey, J. R., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.09.021 · Cited by 32
New and emerging lipid-modifying drugs to lower LDL cholesterol
Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 35
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

